All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial

Trial Details

NCT ID

NCT06636981

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• Cohort2: ATRA+Toripalimab+TPC
• Cohort1: ATRA+Toripalimab+chemo

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806
• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• The subjects voluntarily participate and sign a written informed consent form;
• Age ≥ 18 years old;
• For locally advanced inoperable or metastatic breast cancer confirmed by histology (according to AJCC 8th edition staging), the histology and patho…
• According to RECIST 1.1 criteria for solid tumor evaluation, there must be at least one measurable lesion;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.